$AHCO

WOLF DALE B purchased $127K of AHCO

WOLF DALE B purchased 20,000 shares of AdaptHealth Corp. (AHCO) at $6.37 ($0.13M total) on 2026-08-06.

Original reporting
SEC EDGAR · WOLF DALE B
Published Aug 11, 2026, 12:02 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AHCO
Bullish
low confidence
Mentioned
$AHCO
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AHCOBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase details (20,000 shares at $6.37) and resulting direct holdings (143,234 shares).

02

Market read

Traders may note the insider buy as a small sentiment input, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The filing does not state intent, timing rationale, or whether the director’s broader trading pattern is consistent; without follow-on disclosures, signal strength is weak.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-10 after trade date 2026-08-06

Background

The article is a SEC Form 4 insider transaction disclosure for AdaptHealth Corp., reported by director WOLF DALE B.

Company-level read

Ticker impact

$AHCOBullishLow confidence
Context

AdaptHealth Corp. (AHCO) disclosed a director open-market purchase of 20,000 shares at $6.37 on 2026-08-06 via Form 4.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

Form 4 insider buys can be read as confidence, but the filing provides no guidance, operational update, or material corporate event, and the transaction size is modest relative to typical market-moving thresholds.

Market effects

No clear sector read-through; this is company-specific insider activity without operational or regulatory context.

None indicated.

None indicated.

Counterpoint

Insider open-market buys can be routine diversification or pre-planned liquidity needs, especially without a clear signal on future performance.

Key entities

  • AdaptHealth Corp.

    Subject of the Form 4 insider transaction disclosure (AHCO).

  • WOLF DALE B

    Director who reported the open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AHCOMedAI 8/10

AdaptHealth Cuts 2026 Outlook as Contract Costs Hit Margins

AdaptHealth Corp. (AHCO) cut its 2026 adjusted EBITDA outlook to $490 million to $520 million from $680 million to $730 million, citing margin pressure from West Coast capitated contract costs and a manufacturer price increase. Revenue guidance is $2.85 billion to $2.89 billion. Q2 organic revenue rose 15.9% to $740.3 million. The company agreed to sell Diabetes Health for $235 million.

$AHCOHighAI 9/10

AdaptHealth (AHCO) Q2 2026 Earnings Call Transcript

AdaptHealth (AHCO) reported Q2 2026 net revenue of $740.3 million, up 12.7% year over year, with organic revenue growth of 15.9%. Adjusted EBITDA was $132 million, down 3.2%, and full-year revenue guidance was cut to $2.85-$2.89 billion with adjusted EBITDA of $490-$520 million. The company cited West Coast contract costs and a $30 million supplier price headwind, plus a $235 million diabetes divestiture.

$AHCOMed

AdaptHealth Sells Diabetes Unit to Sharpen Focus on Sleep, Respiratory Growth

AdaptHealth (NASDAQ:AHCO) said it will sell its diabetes unit to focus on sleep and respiratory. The deal is expected to leave about $60 million of overhead costs in continuing operations, with roughly half removed in year one. Q2 revenue grew 16%, including West Coast expansion, while the company works on contract onboarding and supplier rebate terms.

$AHCOHighAI 9/10

Why AdaptHealth Stock Plummeted This Week

AdaptHealth (NASDAQ: AHCO) shares fell about 47% this week after the company reported Q2 results below expectations and issued sharply lower guidance. Analysts expected EPS of $0.15; AdaptHealth posted a loss of $1.07 per share. Sales rose 12.7% to $740.3M but missed forecasts. Full-year sales guidance was cut to $2.85B-$2.89B and EBITDA and FCF ranges were reduced.

$AHCOHighAI 9/10

AdaptHealth Shares Sink After Earnings Miss and Lower Full-Year Guidance

AdaptHealth Corp. (NASDAQ:AHCO) shares fell about 13% premarket after Q2 2026 results missed expectations and the company cut full-year guidance. It reported a net loss of $0.99 per share and revenue of $740.3M versus $848.9M expected. FY revenue guidance was lowered to $2.85B-$2.89B from about $3.49B, with adjusted EBITDA $490M-$520M and free cash flow $80M-$120M.